VIEWPOINT | Foreign price controls threaten U.S. biotech edge
Guest column by Joni Ekstrum, the executive director of the South Dakota Biotech Association
Sen. John Thune has long championed American innovation, free enterprise and national security. As global competition intensifies and the need for economic resilience grows more urgent, we must protect the industries that have powered America’s leadership in medical breakthroughs and biopharmaceutical innovation.
Unfortunately, policies being discussed in Washington, like Most Favored Nation (MFN), undermine that foundation and threaten the future of patients, researchers and manufacturers in South Dakota and across America.
Keep reading with a 7-day free trial
Subscribe to The Dakota Scout to keep reading this post and get 7 days of free access to the full post archives.